Hikma Pharmaceuticals Plc Director/PDMR Shareholding (1827I)
April 12 2022 - 12:49PM
UK Regulatory
TIDMHIK
RNS Number : 1827I
Hikma Pharmaceuticals Plc
12 April 2022
Hikma Pharmaceuticals PLC
Notification and public disclosure of transactions by persons
discharging managerial responsibilities
Said Darwazah
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Said Darwazah
2 Reason for the notification
a) Position/status Executive Chairman
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial ID Code: GB00B0LCW083
instrument, type
of instrument
and identification
code
b) Nature of the Grant of a pledge by Darhold Limited over 650,000
transaction Ordinary Shares of 10 pence each in Hikma Pharmaceuticals
PLC in favour of J.P. Morgan (Suisse) SA. Darhold
Limited is defined as a Person Closely Associated
with the Executive Chairman, who is a director
and shareholder of Darhold.
c) Price(s) and Price(s): GBP0.00p
volume(s) Volume(s): 650,000
d) Aggregated information Aggregated volume: 650,000
Price: GBP0.00p
e) Date of the transaction 11 April 2022
f) Place of the Amman
transaction
Mazen Darwazah
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Mazen Darwazah
2 Reason for the notification
a) Position/status Executive Vice Chairman
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial ID Code: GB00B0LCW083
instrument, type
of instrument
and identification
code
b) Nature of the Grant of a pledge by Darhold Limited over 650,000
transaction Ordinary Shares of 10 pence each in Hikma Pharmaceuticals
PLC in favour of J.P. Morgan (Suisse) SA. Darhold
Limited is defined as a Person Closely Associated
with the Executive Vice Chairman, who is a director
and shareholder of Darhold.
c) Price(s) and Price(s): GBP0.00p
volume(s) Volume(s): 650,000
d) Aggregated information Aggregated volume: 650,000
Price: GBP0.00p
e) Date of the transaction 11 April 2022
f) Place of the Amman
transaction
Mohammed 'Ali' Al-Husry
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Mohammed 'Ali' Al-Husry
2 Reason for the notification
a) Position/status Non-Executive Director
b) Initial notification Initial notification
/Amendment
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a) Name Hikma Pharmaceuticals PLC
b) LEI 549300BNS685UXH4JI75
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
a) Description of Description: Ordinary shares of 10 pence each
the financial ID Code: GB00B0LCW083
instrument, type
of instrument
and identification
code
b) Nature of the Grant of a pledge by Darhold Limited over 650,000
transaction Ordinary Shares of 10 pence each in Hikma Pharmaceuticals
PLC in favour of J.P. Morgan (Suisse) SA. Darhold
Limited is defined as a Person Closely Associated
with the Non-Executive Director, who is a director
and shareholder of Darhold.
c) Price(s) and Price(s): GBP0.00p
volume(s) Volume(s): 650,000
d) Aggregated information Aggregated volume: 650,000
Price: GBP0.00p
e) Date of the transaction 11 April 2022
f) Place of the Amman
transaction
Peter Speirs
Company Secretary, responsible for releasing this
announcement
12 April 2022
+44 (0) 20 7399 2760
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBLGDSCSBDGDD
(END) Dow Jones Newswires
April 12, 2022 12:49 ET (16:49 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From May 2024 to Jun 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2023 to Jun 2024
